- Home
- VTVT vs CMMB Comparison
VTVT vs CMMB Comparison
Compare VTVT & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- CMMB
- Stock Information
- Founded
- VTVT 2015
- CMMB 2004
- Country
- VTVT United States
- CMMB Israel
- Employees
- VTVT N/A
- CMMB N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- VTVT Health Care
- CMMB Health Care
- Exchange
- VTVT Nasdaq
- CMMB Nasdaq
- Market Cap
- VTVT 31.9M
- CMMB 27.0M
- IPO Year
- VTVT 2015
- CMMB N/A
- Fundamental
- Price
- VTVT $17.40
- CMMB $1.68
- Analyst Decision
- VTVT
- CMMB Strong Buy
- Analyst Count
- VTVT 0
- CMMB 3
- Target Price
- VTVT N/A
- CMMB $7.33
- AVG Volume (30 Days)
- VTVT 49.5K
- CMMB 115.6K
- Earning Date
- VTVT 11-12-2024
- CMMB 11-14-2024
- Dividend Yield
- VTVT N/A
- CMMB N/A
- EPS Growth
- VTVT N/A
- CMMB N/A
- EPS
- VTVT N/A
- CMMB N/A
- Revenue
- VTVT $1,000,000.00
- CMMB N/A
- Revenue This Year
- VTVT N/A
- CMMB N/A
- Revenue Next Year
- VTVT N/A
- CMMB N/A
- P/E Ratio
- VTVT N/A
- CMMB N/A
- Revenue Growth
- VTVT 11011.11
- CMMB N/A
- 52 Week Low
- VTVT $7.38
- CMMB $0.42
- 52 Week High
- VTVT $30.99
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- VTVT 68.44
- CMMB 57.63
- Support Level
- VTVT $12.62
- CMMB $1.56
- Resistance Level
- VTVT $15.40
- CMMB $1.90
- Average True Range (ATR)
- VTVT 1.02
- CMMB 0.15
- MACD
- VTVT 0.30
- CMMB 0.04
- Stochastic Oscillator
- VTVT 84.01
- CMMB 59.09
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.